LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
106.33
+0.26 (+0.25%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close106.07
Open106.23
Bid105.50 x 1100
Ask107.05 x 1000
Day's Range105.35 - 106.87
52 Week Range73.69 - 107.84
Volume5,333,680
Avg. Volume3,547,653
Market Cap106.064B
Beta0.48
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateOct 23, 2018
Forward Dividend & Yield2.25 (2.13%)
Ex-Dividend Date2018-08-14
1y Target Est98.07
Trade prices are not sourced from all markets
  • Elanco CEO on IPO, animal health focus
    CNBC Videos2 days ago

    Elanco CEO on IPO, animal health focus

    Jeff Simmons, Elanco CEO, discusses the animal health company's initial public offering at the NYSE.

  • The Wall Street Journal19 hours ago

    [$$] Lilly Approval to Spur Migraine-Prevention Market in Europe

    & Co.’s (LLY) preventive migraine drug galcanezumab has received a positive marketing recommendation from the European Medicines Agency, the company and the regulator said separately on Friday, opening the door to competition in Europe. The approval matters because the drug is one of a new class of compounds that inhibit the activity of a molecule involved in migraine attacks, for which there is currently no cure. Ltd. (TEVA) also received approval from the Food and Drug Administration for its own fremanezumab, after months of delays had weighed on investor sentiment.

  • Market Rallies Despite Trade Worries: 5 Blue-Chip Picks
    Zacks22 hours ago

    Market Rallies Despite Trade Worries: 5 Blue-Chip Picks

    The current momentum in stock markets can primarily attributed to large-cap blue-chip stocks as investors shrugged off trade war jitters.

  • Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults
    PR Newswireyesterday

    Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults

    INDIANAPOLIS, Sept. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality™ (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. In June 2018, Lilly announced the intended brand name, Emgality™, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is an investigational, once-monthly, self-administered injection under evaluation for the prevention of migraine, with no titration needed.

  • Reutersyesterday

    Lilly migraine drug wins European panel thumbs-up

    A European Medicines Agency panel on Friday recommended the approval of U.S. pharmaceutical group Eli Lilly's migraine treatment, bringing the drug one step closer to being sold in the European Union. Emgality, or galcanezumab, which treats episodic cluster headache attacks, was endorsed by the Committee for Medicinal Products for Human Use, a panel whose recommendations are generally followed by European regulators. Lilly's drug belongs to a new class of drugs targeting CGRP to treat migraines.

  • Animal health firm Elanco surges 41 percent on debut
    Reuters2 days ago

    Animal health firm Elanco surges 41 percent on debut

    The company raised $1.51 billion from the offering, which it expects to largely pass on to Eli Lilly and Co (LLY.N). The U.S. drugmaker is expected to own about 82.3 percent of Elanco after the IPO, which was announced in July following a nine-month review of Lilly's businesses which include diabetes and lung cancer drugs.

  • MarketWatch2 days ago

    Elanco Animal Health stock soars more than 35% in trading debut

    Elanco Animal Health Inc. shares soared more than 35% Thursday in their trading debut, after the company priced the stock above its price range. Elanco, a spinoff from Eli Lilly & Co. , issued 62.9 million shares at $24 each, compared with a price range of $20 to $23, to raise $1.51 billion. Goldman Sachs. J.P. Morgan and Morgan Stanley were book-running managers on the deal. Shares are trading on the New York Stock Exchange under the ticker "ELAN."

  • Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
    Zacks2 days ago

    Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

    Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

  • Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
    Market Realist2 days ago

    Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates

    GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • Elanco’s $1.7 billion IPO looks too pricey, and here’s why
    MarketWatch2 days ago

    Elanco’s $1.7 billion IPO looks too pricey, and here’s why

    Elanco Animal Health, the premier animal-health company being spun out of Eli Lilly (LLY) , is expected to begin trading on Thursday. Elanco enters the public market with significant revenue ($2.9 billion in 2017) but falling after-tax profit (NOPAT), and negative GAAP net income. As with any health-care firm, the valuation is based less on current profitability and more on the strength of its product/vaccine portfolio (and their patents) and its success in researching and developing (or acquiring) new animal-health products.

  • Reuters3 days ago

    Lilly's Elanco animal health unit's IPO priced at $24/share

    The initial public offering of Eli Lilly Co's animal health unit, Elanco, was priced above the expected range at $24 per share on Wednesday, giving the company a market capitalization of $8.55 billion. Elanco raised $1.51 billion from the IPO of 62.9 million shares. Lilly, which sold only a minority stake in the IPO, announced the separation of the unit in July following a nine-month review.

  • MarketWatch3 days ago

    Elanco Animal Health prices IPO above expected range

    Elanco Animal Health Inc. priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. , priced shares at $24 a piece. Earlier in the month, Elanco had estimated shares in the $20 to $23 range. Under current pricing, Elanco hopes to raise up to $1.74 billion on an offering of 62.9 million shares with an added 9.4 million to underwriters to cover over-allotments. Following the IPO, Lilly expects to keep an 82.3% stake in Elanco, or 80.2% if over-allotment shares are sold. Goldman Sachs. J.P. Morgan and Morgan Stanley are acting as book-running managers. Shares are scheduled to begin trading under the ticker "ELAN" on the New York Stock Exchange on Thursday.

  • Business Wire3 days ago

    Elanco Announces Pricing of Initial Public Offering

    The shares are expected to begin trading on the New York Stock Exchange (NYSE) on September 20, 2018 under the ticker symbol “ELAN.” The offering is expected to close on September 24, 2018, subject to customary closing conditions. Elanco has granted the underwriters a 30-day option to purchase up to 9.435 million additional shares of common stock at the initial price to the public less underwriting discounts. Following the IPO, Lilly is expected to hold approximately 82.3% of Elanco (80.2% if the underwriters' option to purchase more shares is exercised in full).

  • Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO
    Bloomberg3 days ago

    Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO

    The Eli Lilly & Co.-owned animal medicine maker rose to $32.11 from its $24 offering price at 11:40 a.m. Thursday in New York trading, giving it a market value of $11.7 billion. Elanco priced 62.9 million shares on Wednesday, after marketing them at $20 to $23 each. Elanco already operates fairly independently from its soon-to-be former parent, which will help it move quickly once it’s on its own, according to Chief Executive Officer Jeff Simmons.

  • J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
    Zacks3 days ago

    J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

    Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

  • Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
    Zacks3 days ago

    Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

    Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist3 days ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
    Zacks4 days ago

    Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

    Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

  • Exploring Pharmaceutical Stocks’ Revenue Growth Rates
    Market Realist4 days ago

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • A Look at the Dividends Paid by Pharma Stocks in 2018
    Market Realist4 days ago

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
    Zacks5 days ago

    Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

    Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

  • Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
    Market Realist5 days ago

    Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval

    On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.

  • How Pharmaceutical ETFs Have Performed in 2018
    Market Realist5 days ago

    How Pharmaceutical ETFs Have Performed in 2018

    Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.

  • Competition Dynamics for Ajovy—Teva’s Migraine Drug
    Market Realist5 days ago

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.